{
    "nct_id": "NCT06555263",
    "official_title": "A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1",
    "inclusion_criteria": "* Histologically or cytologically confirmed non-squamous/adenocarcinoma or adenosquamous NSCLC that is either unresectable Stage IIIb/c disease not amenable for definitive chemoradiation, or Stage IV.\n* Age â‰¥ 18 years\n* ECOG performance status 0 to 1.\n* Received at least 2 but no more than 4 prior lines of systemic therapy for advanced NSCLC\n* Disease progression during or following the most recent systemic anti-cancer therapy.\n* Positive FOLR1 expression per central testing\n* At least 1 measurable target lesion per RECIST 1.1\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor\n* Untreated central nervous system metastases\n* Ongoing immunosuppressive therapy, except for treated brain metastases, per criterion above.\n* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment\n* Pre-existing clinically significant ocular disorders, severe chronic obstructive pulmonary disease or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition\n* Previous solid organ transplantation\n* Concurrent participation in another therapeutic treatment trial",
    "miscellaneous_criteria": ""
}